Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study

Menczer, J.; Ben-Baruch, G.; Rizel, S.; Brenner, H.

European Journal of Gynaecological Oncology 13(4): 316-318

1992


ISSN/ISBN: 0392-2936
PMID: 1516581
Document Number: 393062
Effective second line chemotherapy schedules for recurrent ovarian carcinoma are not available. The combination of cisplatin and VP-16 given as a single dose in such patients gave inconsistent results. Since VP-16 is a dose-schedule dependent drug it was given in this pilot study as a continuous 72 hour infusion at a dose of 100 mg/m2/day. No objective response was observed among 7 patients with refractory or recurrent ovarian carcinoma who received a median of 3 treatment courses.

Document emailed within 1 workday
Secure & encrypted payments